QURE

uniQure: 'Hold' AMT-130 U-Turn By FDA For HD Could Possibly Alter Course (NASDAQ:QURE)

uniQure stock upgraded by Wolfe Research on Huntington’s therapy outlook

uniQure N.V. 2026: Revenue $5.84M, EPS ($1.22) — 10-Q Summary

uniQure posts Q2 2026 loss of $81.1M, cash balance $810.3M; BLA for AMT-130 on track

uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

uniQure (QURE) Stock Still Looks Expensive Given Its Huntingtons Promise

uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix

Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?

QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway

Price to earnings forward of uniQure N.V. – BMV:QURE/N

uniQure Prices $45.50 Stock Offering; Underwriting With Leerink Partners Nets $242.7 Million

uniQure (QURE) Stock Sees Fair Value Lift As AMT 130 BLA Plans Rework Risk

UniQure: AMT-130's FDA Path Reaffirms My Bull Case (NASDAQ:QURE)

uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock?

uniQure (QURE) Stock Could Be 49% Undervalued After FDA AMT 130 Update